Login to Your Account

Imetelstat Implodes in Breast Cancer Trial, Geron Swoons

By Marie Powers
Staff Writer

Monday, September 10, 2012

The melancholy on the Geron Corp. conference call early Monday morning was palpable after the company disclosed its decision to halt the Phase II study of imetelstat in metastatic HER2-negative breast cancer after an unplanned interim analysis revealed a greater number of deaths in the treatment arm than the comparator arm.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription